Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Public ClinicalTrials.gov record NCT04657822. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Study identification
- NCT ID
- NCT04657822
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- Crizanlizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Months to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 9, 2021
- Primary completion
- Jun 9, 2031
- Completion
- Jun 9, 2031
- Last update posted
- Apr 6, 2026
2021 – 2031
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Alabama | Birmingham | Alabama | 35233 | Recruiting |
| Childrens National Hospital | Washington D.C. | District of Columbia | 20010 | Active, not recruiting |
| Augusta University Georgia | Augusta | Georgia | 30912 | Recruiting |
| East Carolina University | Greenville | North Carolina | 27834 | Completed |
| East Carolina University | Greenville | North Carolina | 27858 | Completed |
| Childrens Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104-4399 | Active, not recruiting |
| Cook Childrens Medical Center | Fort Worth | Texas | 76104 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04657822, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04657822 live on ClinicalTrials.gov.